9 stories mentioning HKG:2096Updated 20d ago
Every FINWIRES story that references HKG:2096, newest first.
Simcere Pharmaceutical (HKG:2096) said its Culevibart injection, branded Yingmule, received marketing approval from China's National Medical Products Administration.The drug is indicated to prevent lower respiratory tract infections caused by respiratory syncytial virus in newborns and infants entering or born during their first RSV epidemic season, according to a Thursday filing.
Simcere Pharmaceutical (HKG:2096) agreed to grant Roche exclusive global rights to develop, manufacture and commercialize experimental cancer drug, SIM0660, according to a Tuesday Hong Kong bourse filing.Simcere will receive $75 million upfront and is eligible for up to $1.46 billion in milestone payments, plus tiered royalties of up to double digits on future net sales.
Simcere Pharmaceutical Group (HKG:2096) posted an attributable net profit of 828.7 million yuan in the first half, up 37.9% from 601.1 million yuan a year ago.Earnings per share came in at 0.32 yuan, up from 0.25 yuan a year earlier, according to a Friday filing with the Hong Kong Stock bourse.Total revenue in the six months ended June 30 increased to 4.58 billion yuan from 3.59 billion yuan.The company did not declare an interim dividend.
Simcere Pharmaceutical's (HKG:2096) SANBEXIN has been included in the 2026 edition of the National Essential Medicines List.The drug is used for the treatment of acute ischemic stroke, according to a Thursday Hong Kone bourse filing.The company believes the inclusion is beneficial for the product to break through the limitations of class grade III type A (3A) hospitals, accelerate market penetration, and expand terminal prescription scenarios.
Simcere Pharmaceutical (HKG:2096) obtained approval from China's National Medical Products Administration to conduct clinical trials of SIM0689, according to a Friday Hong Kong bourse filing.The company intends to evaluate the PD-1/VEGF bispecific antibody in patients with advanced solid tumors.
Simcere Pharmaceutical (HKG:2096) entered into an exclusive promotion service agreement with PrimeGenX Therapeutics for Pumecitinib Gel, a Monday Hong Kong bourse filing said.Under the agreement, Simcere obtained exclusive promotion rights for the drug's dermatology indications in mainland China, Hong Kong, and Macau.Pumecitinib Gel is described as the "world's first" JAK inhibitor gel for atopic dermatitis and is also being developed for additional dermatology indications, including atopic dermatitis in children aged 2 to 11, prurigo nodularis, and non-segmental vitiligo, according to the filing.
Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.
Simcere Pharmaceutical's (HKG:2096) resubmitted new drug application for Rademikibart was accepted by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The acceptance is for the use of the drug, which was jointly developed by the firm and Connect Biopharma Hong Kong, for the treatment of atopic dermatitis in adults and adolescents.
Simcere Pharmaceutical (HKG:2096) posted profit attributable to equity shareholders of 1.34 billion yuan for 2025, up 86% from 722 million yuan a year earlier, according to a Tuesday Hong Kong bourse filing.Shares of the pharmaceutical firm were down 1% in recent trade.Earnings per share came in at 0.54 yuan from 0.29 yuan a year earlier.Revenue rose 16.5% to 7.73 billion yuan from 6.64 billion yuan in 2024.
